Home » FDA Guidance Offers Efficacy Endpoints for TB Clinical Trials
FDA Guidance Offers Efficacy Endpoints for TB Clinical Trials
Sponsors designing clinical trials for drugs or multi-drug regimens for treatment of tuberculosis should focus on one of three endpoints: no growth of M. tuberculosis on sputum cultures during treatment; an endpoint comprised of survival and evaluation of M. tuberculosis on serial sputum culture examinations during treatment and 12 months following treatment; and improvement or resolution of symptoms when therapy is completed.
Drug Industry Daily
Drug Industry Daily
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May